Completion of placing of new h shares under general mandate
Filed with HKEX · Stock code 2565 · · 3 pages · English
Summary by 6ix AI
PegBio Co., Ltd. has announced the completion of the placing of new H shares under a general mandate, fulfilling all conditions of the Placing Agreement. The proceeds from this placing are intended for research and development, loan repayment, and general corporate purposes. The announcement also details the expected timeline for utilizing the proceeds, which is subject to change based on market conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PegBio
- Cancellation of extraordinary general meeting and cancellation of book closure period
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Placing of new h shares under general mandate
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
- Notice of the 2026 first extraordinary general meeting
Later from PegBio
- Next Day Disclosure Return
- (1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 26, 2026
- Voluntary announcement successful inclusion of the group's core product paidakang (visepegenatide injection) into the 2026 NRDL
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio